Oncolytics Biotech has redirected resources toward registrational and registration-enabling studies in anal and colorectal cancer after concluding enrollment in its GOBLET gastrointestinal trial. This disciplined approach targets indications where pelareorep has shown the greatest efficacy, aiming for efficient approval paths without broad-based dilution.

In third-line squamous cell anal cancer patients, GOBLET Cohort 4 reported a 29% objective response rate with a median duration of response around 17 months—outcomes more than double existing benchmarks in a setting lacking FDA-approved options. These results have clarified trial endpoints and strengthened the case for single-arm approval studies.

Pelareorep’s Fast Track Designation for second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer follows Phase 2 data showing a 33% response rate versus roughly 10% with chemotherapy and Avastin®, and median overall survival of 27 months versus 11.2 months. This indication represents a $3 billion–$5 billion annual market opportunity.

With a cash runway sufficient to execute near-term programs without immediate dilution, Oncolytics plans a mid-April FDA meeting to finalize registrational trial designs for studies under 100 patients. The first site activation is slated for March, with interim data expected by year-end 2026.